Halozyme Therapeutics Inc (HALO): Another strong finish with high volume....

Another strong finish with high volume. No option

biotechinvestor1 · 2025-03-24T20:06:12.1800000Z

Another strong finish with high volume. No option expiry to explain this one.

Play Episode

6min

Proactive - Interviews for investors

BioHarvest Sciences reports record-breaking 2024 revenue and expansion milestones

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to discuss the company’s impressive financial and operational performance for the fourth quarter and full year ended December 31, 2024. The company reported a remarkable 62% increase in fourth-quarter revenues, reaching $7.3 million, while full-year revenue surged by 99% year-over-year to $25.2 million, surpassing prior guidance. A key driver of this growth has been the continued expansion of VINIA®, BioHarvest’s flagship product line. As of February 2025, total VINIA® subscribers exceeded 50,000, contributing to a cumulative revenue milestone of $50 million since launch. Building on this momentum, the company successfully introduced its VINIA SuperFood Tea line, leveraging its "VINIA Inside" strategy following the successful launch of VINIA SuperFood Coffee in December 2023. Beyond its financial success, BioHarvest achieved several strategic milestones in 2024. Sobel highlighted a groundbreaking partnership with Tate & Lyle to develop plant-based sweeteners, further validating BioHarvest’s innovative Botanical Synthesis platform. Additionally, the company expanded its VINIA product portfolio and completed a successful uplisting to the Nasdaq Global Market, strengthening its position for accelerated growth and operational efficiency in 2025. With a strong foundation and continued product innovation, BioHarvest Sciences is poised to drive further market expansion and deliver sustained shareholder value in the coming year. #proactivinvestors #nasdaq #bhst #pharma #biotech #hearthealth #fattyliverdisease #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #IlanSobel #VINIA #HealthTech #Biotech LiverHealth #OliveCell #Verbascoside #NonAlcoholicFattyLiver #SupplementScience #HealthInnovation

Proactive - Interviews for investors

Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones

Trevi Therapeutics CEO Jennifer Good joined Steve Darling from Proactive to discuss the company’s progress in advancing its cough treatment pipeline using nalbuphine, a mixed agonist-antagonist opioid. Originally developed for acute indications, nalbuphine is now being repurposed due to its dual mechanism of action, working both peripherally in the lungs and centrally in the brainstem, offering a novel approach to treating chronic cough disorders. Trevi initially explored multiple indications, including skin conditions caused by severe itching and neurological cough. However, compelling clinical data led the company to focus on cough-related indications. Good explained, “We thought our drug was different because not only does it work peripherally in the lung, it works centrally at the brain, which mediates coughing and breathing.” The company is now targeting three key areas: interstitial lung diseases (including idiopathic pulmonary fibrosis, or IPF), refractory chronic cough (RCC), and other neurological cough conditions. Following promising Phase 2a results in RCC—an area where many previous drug candidates have failed—Trevi is preparing for a Phase 2b dose-ranging study. If successful, only one pivotal study may be required before regulatory filing. Good also highlighted Trevi’s strong financial position, noting that the company has sufficient cash runway to support its current studies through the second half of 2026, including further development in RCC and IPF. #proactiveinvestors #trevitherapeuticsinc #nasdaq #trvi #JenniferGood #Nalbuphine #ChronicCough #RefractoryCough #Phase2aResults #BiotechNews #PharmaPipeline #IPF #ClinicalTrials #CoughTreatment #NeurologicalDisorders #ProactiveInvestors

Proactive - Interviews for investors

Itaconix CEO on 2025 strategy and profitability goals

Itaconix PLC (AIM:ITX, OTCQB:ITXXF) CEO John Shaw joined Steve Darling from Proactive to provide an update on the company’s progress following its strategic restructuring and to discuss what lies ahead for 2025. Shaw highlighted that the company ended 2024 with strong momentum, achieving nearly $3.7 million in revenue in the second half, marking one of its highest-ever earnings periods. The restructuring initiative focused on enhancing profitability, with a significant emphasis on reshaping the customer base. Shaw noted, “We actually increased our gross profit margin from about 31% to almost 35% last year.” Despite experiencing lower revenue in some areas, the company was able to maintain steady gross profits due to its emphasis on margin improvement. Shaw also discussed significant product developments, including the launch of Itaconix TSI 422, a new detergent ingredient that is gaining traction in North America and Europe. He further explained how the SPARX program, introduced in October, is helping accelerate customer collaboration in key product categories, positioning the company for continued growth. In addition to product development, the company has made strategic investments in its operations, marketing, and regulatory capabilities to support its growth trajectory. Shaw expressed confidence in the company’s production team and infrastructure, stating, “We really have everything in place we need right now to have a great run over the next 24 months.” While tariffs remain a consideration, Shaw believes any impacts will be manageable, and in some cases, could even be beneficial to the company. #proactiveinvestors #itaconixplc #aim #itx #otcqb #itxxf #SustainableChemicals #CleanTech #TSI422 #SPARXProgram #SpecialtyChemicals #JohnShaw #InvestorUpdates #ProactiveInvestors #GreenChemistry #DetergentInnovation #GrossProfitMargins #RestructuringSuccess

Proactive - Interviews for investors

Nextech3D.ai disrupts industry with launch of AI-powered Ecommerce content studio

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce the launch of a new AI-powered feature as part of the company’s Ecommerce AI Studio. The platform utilizes generative AI to create photorealistic lifestyle images and videos of products—such as apparel, accessories, and furniture—being worn, held, or displayed in realistic settings, eliminating the need for traditional photography. Gappelberg highlighted that ToggleStudios, Nextech3D.ai’s AI-driven content creation tool, is designed to help online retailers generate lifestyle content at scale. The platform reduces reliance on costly and time-consuming physical photoshoots, enabling faster content production, lower operating costs, and increased visual output. The new feature will allow users to generate AI-rendered images of apparel on virtual models with varied backgrounds and appearances. Additionally, retailers can visualize accessories, electronics, and other items in realistic usage scenarios, enhancing product presentation for e-commerce. Another major upgrade is the automated generation of product videos and interactive 3D visuals. Using advanced AI, the system simulates lighting, texture, and perspective, ensuring high-quality imagery that closely replicates traditional photography—but in less time and at a lower cost. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #AmazonSellerCentral #3DModeling #AIPhotography #EcommerceInnovation #3DTechnology #LifestylePhotography #ProactiveInterviews #TechInnovation #AmazonPartners#proactiveinvestors #nextech3d.al

Followers	3
Posts	1317
Boards Moderated	0
Alias Born	02/07/2016

Volume:	2,021,006
Day Range:	56.93 - 61.37
Bid:	57.00
Ask:	63.00
Last Trade Time:	5:37:18 PM EDT
Total Trades:	31,352

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

HALO Detailed Quote

Recent HALO News

More HALO News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent HALO News

Go Ad-Free